Australia’s rules for accessing nicotine products changed significantly through 2024, and the details can be confusing. This page explains, in plain terms, the two legal pathways - Schedule 3 and Schedule 4 - how they differ, and where nicotine replacement therapy fits as the first-line option. It’s general information about the regulatory framework, not medical advice or a recommendation to use any product.
What Are Schedule 3 (S3) Nicotine Products?
Schedule 3 means “Pharmacist Only Medicine”. For therapeutic nicotine vaping products, the Schedule 3 pathway allows a pharmacist to supply a product to an adult without a prescription, following a consultation. The key criteria are:
-
Adults only (18+). Under-18s cannot access the pharmacist pathway.
-
Up to 20 mg/mL nicotine. Products at or below this concentration fall within Schedule 3.
-
A pharmacist consultation is required. The pharmacist assesses suitability and provides guidance - it isn’t an over-the-counter purchase.
-
Supply limits apply. Pharmacists supply within defined quantity limits, not open-ended amounts.
|
State and territory variation - important. The Schedule 3 pharmacist pathway does not operate the same way everywhere. Some jurisdictions - including Western Australia - have chosen to require a prescription for therapeutic nicotine products regardless, so the pharmacist-only pathway may not be available there. Because state law can differ and continues to change, always check the current rules with a pharmacist in your own state or territory. |
What Are Schedule 4 (S4) Nicotine Products?
Schedule 4 means “Prescription Only Medicine”. A therapeutic nicotine vaping product falls into Schedule 4 - requiring a prescription from a doctor or nurse practitioner, in situations such as:
-
Above 20 mg/mL nicotine. Higher-concentration products sit in Schedule 4.
-
Patients under 18. For a young person, access requires a prescription and appropriate clinical oversight.
-
More complex circumstances. Where a prescriber judges that medical supervision is appropriate.
In these cases, a registered doctor or nurse practitioner assesses the person and, where clinically appropriate, prescribes the product, which is then dispensed by a pharmacy.
Script vs Pharmacy: Comparing the Access Pathways
Here’s how the two pathways compare side by side. Which one applies depends mainly on the nicotine concentration, the person’s age, and the rules in their state or territory.
|
|
Schedule 3 - Pharmacist Only |
Schedule 4 - Prescription Only |
|
Do you need a prescription? |
No - supplied after a pharmacist consultation. |
Yes - from a doctor or nurse practitioner. |
|
Nicotine concentration |
Up to 20 mg/mL. |
Above 20 mg/mL. |
|
Who it’s for |
Adults 18 and over. |
Under-18s, or adults needing higher strength or oversight. |
|
Who supplies it |
A pharmacist, following a consultation. |
A pharmacy, dispensing against a prescription. |
|
Availability |
Where state/territory law permits (not all - e.g. WA). |
Available nationally through the prescription pathway. |
General guide only. Rules vary by state and territory and continue to change - confirm the current position with a pharmacist. Sources: TGA vaping hub; Pharmaceutical Society of Australia.
How Australia’s Nicotine Scheduling Has Changed
The current two-pathway system results from reforms over several years. A short timeline helps make sense of it:
-
October 2021 - nicotine vaping products became prescription-only (Schedule 4) nationally, meaning a doctor’s prescription was needed to access them legally.
-
2024 - vaping reforms. Under the Therapeutic Goods and Other Legislation Amendment (Vaping Reforms) Act 2024, therapeutic vaping products moved into pharmacies as the lawful supply channel, with strengthened product standards.
-
1 October 2024 - the Schedule 3 pathway began. From this date, pharmacists could supply therapeutic vaping products up to 20 mg/mL to adults without a prescription (Schedule 3), while higher strengths and under-18s remained prescription-only (Schedule 4).
-
Since then - ongoing change. Product standards have continued to tighten, and some states and territories have set their own rules on the pharmacist pathway.
Because this area is still evolving, the most current position is always on the TGA vaping hub.
How the myduke® Pathway Works With Both Options
myduke® is an online Australian service that connects adults with independent AHPRA-registered doctors and works with licensed dispensing pharmacies. For people whose circumstances point to the prescription pathway, the process is subsidised or PBS-listed, like some NRT, straightforward and clinically overseen:
-
1. Complete an online assessment - a confidential questionnaire about your health and nicotine use.
-
2. Independent doctor review - an AHPRA-registered doctor assesses your information and decides whether treatment is clinically appropriate.
-
3. Licensed pharmacy dispensing - where a product is prescribed, it’s dispensed by a licensed Australian pharmacy.
-
4. Ongoing support - follow-up and review are part of the pathway.
Completing an assessment doesn’t guarantee a treatment plan or a particular product - an independent doctor decides what’s appropriate. And importantly, that conversation starts with first-line options, not with nicotine products.
Important Safety and Compliance Considerations
Therapeutic nicotine vaping products are unapproved therapeutic good inhalers. That means the TGA has not assessed them for safety, quality, or efficacy the way registered medicines are, and they are not a first-line treatment. Some, such as Western Australia, TGA-registered nicotine replacement therapies - patches, gum, lozenges, mouth spray and inhalators - which you can read about in our guide to nicotine replacement therapy. Australian clinical guidance recommends trying these first, alongside behavioural support, before considering a therapeutic vaping product.
Nicotine is addictive, and therapeutic nicotine products are intended only as part of a supervised plan to stop smoking - not as a long-term habit or a lifestyle product. Anyone considering this pathway should do so with a doctor or pharmacist, and with complete smoking cessation as the goal. None of this is subsidised or PBS-listed like some NRT.
Frequently Asked Questions
What is the difference between Schedule 3 and Schedule 4 medicines?
In Australia’s Poisons Standard, Schedule 3 means “Pharmacist Only Medicine” - a pharmacist can supply it after a consultation, without a prescription. Schedule 4 means “Prescription Only Medicine” - you need a prescription from a doctor or nurse practitioner. For nicotine products, the concentration (20 mg/mL), the person’s age, and state law decide which applies.
Which forms of nicotine are legal in Australia?
Nicotine replacement therapies - patches, gum, lozenges, mouth spray and inhalers - are legal, registered and available over the counter, and are the first-line option. Therapeutic nicotine vaping products are legal only through the pharmacist (Schedule 3) or prescription (Schedule 4) pathways described above. Nicotine products bought outside these channels - from the illicit market - are neither legal nor quality-assured.
Are therapeutic nicotine vaping products a first-line treatment?
No. They are unapproved goods and are not first-line. Australian clinical guidance recommends registered NRT and behavioural support first. A therapeutic vaping product is generally only considered where first-line options haven’t worked, and always with clinical oversight and complete cessation as the aim.
Does the pharmacist-only (S3) pathway apply in every state?
No. The Schedule 3 pharmacist pathway is set nationally, but states and territories can apply their own rules, and some, such as Western Australia, require a prescription regardless. Because this varies and keeps changing, check the current position with a pharmacist in your state or territory.
Are these products subsidised by the government?
No - therapeutic nicotine products are not PBS-subsidised. Some nicotine patches, by contrast, are PBS-subsidised with a prescription, which is one of several reasons registered NRT is the first-line option. Free NRT is also available through Quitline in some states.
The Bottom Line
Australia’s nicotine scheduling has two lawful pathways: Schedule 3, where a pharmacist can supply lower-strength therapeutic nicotine vaping products to adults after a consultation (where state law allows), and Schedule 4, which requires a prescription. Both sit within a regulated framework, and both treat these products as what they are - unapproved goods, not a first-line treatment.
If you’re looking to quit, the best-evidenced place to start is registered NRT and support, not a vaping product. If you’d like a clinical view of your options, an independent AHPRA-registered doctor reviews an assessment through myduke®. You can also read about doctor-led treatment options and how the pathway works.
|
Important information This article provides general information about Australia’s regulatory framework only. It is not medical advice, and it is not a recommendation to use any nicotine product. The relevant registered practitioner or pharmacist determines treatment suitability and supply independently after consultation, and requirements differ between states and territories. myduke® is a clinical health service. Under Australian law, therapeutic nicotine products are unapproved goods. They are only available to patients 18+ for smoking cessation or nicotine dependence following a consultation with a pharmacist (for ≤20mg/mL) or a prescription from a medical practitioner (for >20mg/mL). Always read the label and follow practitioner advice. |